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ABSTRACT Introduction: Military deployments relocate service members to austere locations with limited medical
capabilities, raising uncertainties whether members with diabetes can participate safely. Military regulations require a
medical clearance for service members with diabetes prior to deployment, but there is a dearth of data that can guide
the provider in this decision. To alleviate the lack of evidence in this area, we analyzed the change in glycated hemoglobin (HbA1c) and body mass index (BMI) before and after a deployment among active duty U.S. Air Force personnel who deployed with diabetes. Materials and Methods: A retrospective analysis was conducted using HbA1c and
BMI values obtained within 3 mo before and within 3 mo after repatriation from a deployment of at least 90 d between
January 1, 2004 through December 31, 2014. The study population consisted of 103 and 195 subjects who had an
available pre- and post-deployment HbA1c and BMI values, respectively. Paired t-tests were conducted to determine
signiﬁcant differences in HbA1C and BMI values. Results: The majority (73.8%) of members had a HbA1c <7.0%
(53 mmol/mol) prior to deployment. For the overall population, HbA1c before and after deployment decreased from
6.7% (50 mmol/mol) to 6.5% (40 mmol/mol) (p = 0.03). Subgroup analysis demonstrated a signiﬁcant decline in
HbA1c among males, those aged 31–40 yr, and those with a pre-deployment HbA1c of >7%. BMI declined for the
overall population (28.3 kg/m2 vs. 27.7 kg/m2, p < 0.0001) and for most of the subgroups. Conclusion: Air Force service members who deployed with diabetes, including those with a HbA1c > 7%, experienced a statistically signiﬁcant
improvement in HbA1c and BMI upon repatriation. A prospective study design in the future can better reconcile the
effect of a military deployment on a more comprehensive array of diabetes parameters.

The continuing rise of diabetes in the U.S. threatens to affect
even those whose occupations require physical ﬁtness. The
U.S. Armed Forces require service members to meet physical ﬁtness and anthropometric standards, yet despite their
active lifestyles, they remain vulnerable to developing diabetes. It is estimated that nearly 3% of U.S. service members
have diabetes.1 A study by Paris et al characterizing U.S.
service members who develop type 2 diabetes suggests that
the mean age at diagnosis is 35.2-yr old, affected after an
average of 13.6 yr of military service.2 Despite a lifetime of
adherence to physical ﬁtness standards, diabetes can still
affect service members at the height of their military careers.
Having a chronic medical condition does not necessarily
preclude continued military service. However, diabetes
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presents unique occupational challenges. Chief among them
is the geographic limitation that diabetes imposes due to certain physiologic limitations, environmental challenges, and
the lack of reliable medical access in certain duty locations.
However, the U.S. military has been involved in areas of
conﬂict globally over the past two decades3 and, inevitably,
some members with diabetes have been deployed to these
locations despite their condition. From beginning to end, a
deployment involves physical and physiologic challenges
that can derail a patient’s personal strategy to maintain glycemic control. The journey alone to these operational areas
can involve days of overseas travel, heavy load carriage, and
multiple changes in time zones, causing disruption of regular
sleep, diet, and activity routines. Some operational areas can
be quite austere and geographically unforgiving, marked by
temperature extremes, high altitudes, and unsanitary conditions.4 For the same reasons, medical capability in these
regions may be limited to a medic or individual ﬁrst-aid.
To protect its members, the U.S. Department of Defense
(DoD) requires medical clearance for all members prior to
deployment. Military medical providers are given the discretion to concur with a deployment if they anticipate that a
chronic medical condition will not unexpectedly worsen in a
deployed environment.5 However, there is a dearth of information regarding the glycemic effects of living in challenging circumstances such as a military deployment, and thus, the
DoD lacks speciﬁc guidance in this domain. Current literature
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RESEARCH DESIGN AND METHODS
Data were collected from the Military Health System (MHS)
Management Analysis and Reporting Tool, which contains
health care service data provided by military treatment facilities,
civilian providers, hospitals, managed care support contractors,
the Defense Manpower Data Center, and the Pharmacy Data
Transaction Service, including inpatient, outpatient, pharmaceutical, and enrollment data. Laboratory data came from the MHS
Composite Health Care System.
The study population included active duty members of the
U.S. Air Force with a diagnosis of diabetes who completed
a deployment of at least 90 d between January 1, 2004 and
December 31, 2014. Deployed U.S. Air Force members
included all regular Air Force active duty personnel as well as
members of the Air National Guard and Air Force Reserve who
were activated for deployment. Diabetes was deﬁned by the
presence of a “Diabetes Mellitus” diagnosis according to the
Healthcare Effectiveness Data and Information Set (HEDIS)
criteria. HEDIS methodology identiﬁes patients with diabetes
by evidence of either a diabetes-related diagnosis code in claims/
encounter data or a dispensed diabetes-related medication in
pharmacy data within the past 24 mo. Subjects were excluded
from analysis if their diagnosis was made after December 31,
2014, if they deployed for less than 90 d, if they did not have an
HbA1c or BMI available within 3 mo prior to deployment and
within 3 mo upon repatriation, or if the member became pregnant during deployment or within 3 mo upon repatriation.
The blood samples for HbA1c and BMI measurements
were obtained at any of the U.S. military treatment facilities
worldwide either for a pre- or post-deployment medical evaluation or another form of clinical encounter unrelated to
deployment. The HbA1c and BMI values that were included
in the analysis were those collected at the time most proximal to, but within 3 mo of, the deployment date and at the
time most proximal to, but within 3 mo of, the date of
repatriation.
The presence of comorbid conditions before and after
deployment was identiﬁed through relevant ICD-9 diagnosis
codes. Diabetes-related medication data were collected by
querying for relevant American Hospital Formulary Service
therapeutic classes. Counts of the number of dispenses per
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therapeutic class by time period (before, during, and after
deployment) were calculated for each individual.
The study protocol was approved by the Air Force Regional
Institutional Review Board at Wilford Hall Ambulatory Surgical
Center (WHASC) and the Defense Health Agency Privacy
Ofﬁce prior to data collection.
Analysis was conducted using SPSS version 19. Univariate
analysis allowed for a description of the population including
demographic characteristics, medication, comorbidities, and
clinical measures before and after deployment. In addition,
paired t-tests were conducted to determine signiﬁcant differences in HbA1c and BMI before and after deployment. Paired
t-tests were conducted in stages including the overall group,
those not on medication, and subgroups according to medication regimen. Additional subgroups were analyzed according
to BMI and HbA1c categories.
RESULTS
We identiﬁed 366 U.S. Air Force members with a diagnosis
of diabetes at the time of deployment of at least 90 d
between January 1, 2004 and December 31, 2014. Paired
pre- and post-deployment HbA1c and BMI were available
for 103 (28.1%) and 195 (53.3%) members, respectively.
These members were included in the analysis. Other members not included in the analysis were 97 (26.5%) who had
paired HbA1c drawn beyond the 3-mo window of departure
and repatriation, 43 (11.8%) with an unpaired HbA1c drawn
prior to deployment only, 33 (9%) with an unpaired HbA1c
drawn after deployment only, and 90 (24.6%) without any
HbA1c values within the 3-mo window. The mean HbA1c
for those who had a pre-deployment value only was 6% (42
mmol/mol).
Table I summarizes the characteristics of members with
paired pre- and post-deployment HbA1c. The majority were
men (88.3%) and most were in the 31–50 age group (83.5%).
The majority were in the enlisted corps (74.8%), consistent with
the 4-fold preponderance of enlisted personnel compared with
ofﬁcers in the U.S. Air Force.11 About half had coexisting diagnoses of lipid disorders and/or hypertension. Only a minority
were diagnosed with microvascular complications.
Most of the members (83.5%) were prescribed at least
one diabetes medication at the time of deployment, most
commonly metformin (n = 71, 82.6%), followed by sulfonylureas (n = 27, 31.4%), dipeptidyl peptidase-4 (DPP-4) inhibitors (n = 21, 24.4%), and thiazolidenediones (TZD) (n = 13,
15.1%). None were on meglinitides, alpha-glucosidase inhibitors, or sodium-glucose co-transporter-2 (SGLT-2) inhibitors.
Insulin, the most common injectable medication in the group,
was prescribed to 9 (10.5%) members. Glucagon-like-peptide1 receptor agonists (GLP-1 RA) were prescribed to 3 (3.5%)
members. There were no members on an amylin analog. Half
(n = 43, 50%) were on monotherapy while 36% were on
dual therapy, most commonly metformin plus a sulfonylurea.
Metformin plus TZD and metformin plus a DPP-4 inhibitor
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on the military experience with diabetes has been limited to
case reports and observation of those with type 1 diabetes6–10
who are almost always restricted from deployment or continued military service. We recognized the need to further explore
this area of military medicine in order to guide providers in
their medical decision-making and potentially inﬂuence future
medical defense policies. Therefore, we conducted a retrospective analysis to characterize U.S. Air Force members with diabetes who have deployed, to include their diabetes treatment,
and to analyze the changes in their HbA1c and BMI before
and after a deployment.

Effect of Military Deployment on Diabetes Mellitus in Air Force Personnel
TABLE I. Characteristics of the Study Sample with Paired
Pre- and Post-Deployment HbA1ca (n = 103)
Variable

Number (%)
91 (88.3)
12 (11.7)
8 (7.8)
40 (38.8)
46 (44.7)
9 (8.7)
26 (25.2)
77 (74.8)
48 (46.6)
59 (57.3)
2 (1.9)
0 (0)
1 (1.0)
17 (16.5)
86 (83.5)
76 (73.8)
19 (18.4)
3 (2.9)
5 (4.9)

a

Data reﬂect status prior to deployment.
Ofﬁcers include personnel with ranks second Lieutenant to General and
Warrant Ofﬁcers.
c
Enlisted include personnel with ranks Airman Basic to Chief Master
Sergeant of the Air Force.
b

were the second and third most common dual regimen,
respectively.
Changes in HbA1c
The majority (73.8%) of members had a HbA1c <7.0% (53
mmol/mol) prior to deployment (Table I). Comparing values
before and after deployment, mean HbA1c decreased from
6.7% (50 mmol/mol) to 6.5% (48 mmol/mol), which was a statistically signiﬁcant change (p = 0.03). Those who deployed
with a HbA1c >7% also experienced a signiﬁcant decline in
HbA1c from 7.9% (63 mmol/mol) to 7.1% (54 mmol/mil) (p =
0.0029), as did the males and those in the age 31–40 subgroups
(Fig. 1).
Figure 2 illustrates the HbA1c responses among various
medication subgroups. None of these subgroups demonstrated
a statistically signiﬁcant change in pre and post-deployment
HbA1c values. However, it is worth noting that, in almost all
of the oral medication subgroups, pre and post-deployment
HbA1c values were <7%. In contrast, the insulin subgroup
maintained their mean HbA1c above 7%.
Changes in BMI
At the time of deployment, the mean BMI for the overall
population was in the overweight category (BMI 28.3 kg/m2).
MILITARY MEDICINE, Vol. 183, November/December 2018

CONCLUSIONS
It is imperative that the deliberations to deploy a service
member with diabetes consider all the factors that can compromise the member’s safety and the ability to accomplish
the mission. Herein, we provide objective data to illustrate
the glycemic and BMI responses to a military deployment
among U.S. Air Force members with diabetes. We anticipate
that these ﬁndings would be of value not only to military
medical providers and leaders, but also to the general network of providers who care for service members and are
asked to comment on their deployment candidacy.
We deemed that a HbA1c of <7% is an appropriate
threshold for deployment based on the American Diabetes
Association’s (ADA) recommended HbA1c target for most
adults,12 particularly in a relatively young and healthy population. In this study, most members were meeting this HbA1c
standard prior to deployment, which improved further upon
repatriation, reﬂecting a change that was statistically signiﬁcant. Excluding any diabetes-related complications, a HbA1c
that remained <7% upon repatriation would suggest that the
member likely escaped troublesome glycemic excursions during course of their deployment. For a military provider who
can exclude any history of severe hypo or hyperglycemic episodes during a service member’s deployment, a relatively stable HbA1c upon repatriation is an encouraging ﬁnding. Our
results show that, across multiple subgroups, well-managed
diabetes prior to deployment remained so after deployment.
Even those with HbA1c above an ideal target prior to deployment experienced a signiﬁcant improvement upon return.
HbA1c and Medications
We paid particularly close attention to our population’s medication regimen as certain medications with unfavorable side
effect proﬁles or complicated administration can disqualify a
member from deployment. It is logical that the most salutary
pharmacologic regimen in deployment consists of oral medications due to their ease of administration and durability
during travel.13 Military providers recognize this as members in our study who required diabetes medications were
usually on oral agents. The most commonly prescribed medication was metformin, consistent with the ADA, American
Association of Clinical Endocrinologists (AACE), and
Veterans’ Affairs (VA)/DoD clinical practice recommendations.12–15 For those who tolerate metformin, we agree that
metformin has an adequate safety proﬁle for deployment.
Our data also demonstrate that those who deployed on
e605
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Gender
Male
Female
Age groups
18–30
31–40
41–50
51+
Rank
Ofﬁcersb
Enlistedc
Comorbidities
Hypertension
Lipid disorders
Retinopathy
Nephropathy
Neuropathy
No diabetes medication prescribed
Diabetes medication(s)prescribed
HbA1c
<7%
7–7.9%
8–8.9%
≥9%

Over the course of deployment, the mean BMI demonstrated a
statistically signiﬁcant decline from 28.3 kg/m2 to 27.7 kg/m2
(p < 0.0001). Most of the subgroups also experienced a significant decline in BMI except for ofﬁcers and those over age 50.
The decline in BMI was unrelated to the pre-deployment
HbA1c (Fig. 3).
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9
*

8
*

*

*

6
5
4

HbA1c before deployment

3

HbA1c after deployment

2
1
0
Overall
Male
(n = 103) (n = 91)

Female
(n = 12)

Age
18–30
(n = 8)

Age
31–40
(n = 40)

Age
41–50
(n = 46)

Age >50
(n = 9)

Officers
(n = 26)

Enlisted
(n = 77)

HbA1c
<7%
(n = 76)

HbA1c
≥7%
(n = 27)

FIGURE 1. HbA1c before and after deployment for the overall population and subgroups. Data represents mean HbA1c +/− SE. *p < 0.05. †[10.93 ×
HbA1c%]–23.5 = mmol/mol.

10
9

HbA1c (%)†

8
7
6
5
HbA1c before deployment

4

HbA1c after deployment

3
2
1
0
No medications
(n = 17)

Metformin
Only
(n = 35)

Metformin +
All SU‡
DPP4 Inhibitor regimens w/out
(n = 12)
Insulin (n = 22)

Insulin
(n = 9)

FIGURE 2. HbA1c before and after deployment based on therapeutic interventions. Data represents mean HbA1c +/− SE for those with paired HbA1c
values. †[10.93 × HbA1c%]–23.5 = mmol/mol. ‡Sulfonylurea-containing.

30
*

BMI (kg/m2)

29

*

*

*

*

*
*

28
27

BMI before deployment
BMI after deployment

26
25
24
Overall
Male
Female
(n = 195) (n = 142) (n = 53)

Age
18–30
(n = 45)

Age
31–40
(n = 75)

Age
41–50
(n = 65)

Age >50
(n = 10)

Officers Enlisted
(n = 42) (n = 153)

HbA1c‡
<7%
(n = 57)

HbA1c‡
≥7%
(n = 15)

FIGURE 3. BMI before and after deployment for the overall population and subgroups. Data represents mean BMI +/− SE. *p < 0.05. ‡Data represents
those with paired HbA1c and BMI values.

metformin monotherapy maintained their HbA1c within a
good range.
The ﬁnding that members on sulfonylureas and insulin
were cleared to deploy was surprising. Sulfonylureas and
insulin are known to cause hypoglycemia, an unacceptable
e606

risk in deployment particularly for those who are intensively
controlled.16,17 Nevertheless, we found that sulfonylureas
were the second most common oral therapy prescribed and
the most common medication combined with metformin. It
is unclear to what extent hypoglycemia occurred in these
MILITARY MEDICINE, Vol. 183, November/December 2018
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also be potentially safe in certain deployment settings if adequate storage facilities are available. FDA approval for
SGLT-2 inhibitors fell at the end of our study period,21 but
this class is not likely to be utilized often due to the concern
for volume depletion. TZDs may also be safe in deployment,
but at the time of our study period, there were safety concerns regarding its role in heart failure and bladder cancer,18
leaving metformin and sulfonylureas as the most popular
oral options. As providers gain familiarity with newer
agents, perhaps future deployers requiring diabetes medications will be placed on those with better safety proﬁles.
BMI and Physiologic Challenges Affecting HbA1c
The decline in BMI seen in our population coincides with
the ﬁndings in existing literature on body composition
changes following military deployments, particularly those
that are less than 7 mo in duration. Studies on U.S. and
British soldiers who deployed to Afghanistan for 4–9 mo
reduced their body mass by 2–5% reﬂecting a decrement in
both fat and lean mass.22–24 However, other studies with longer deployment durations suggest that lost body weight tends
to recover, or even exceed pre-deployment weights, potentially owing to an increase in fat mass.25,26
Reduction in weight has been shown to improve glycemic
control12,14,15,27 and our results coincide with the literature.
Although our results demonstrate favorable and concordant
ﬁndings in terms of HbA1c and BMI responses to deployment, glycemic management can be affected other physiologic challenges in a deployed setting, which may be subject
to future systematic analyses.
A physiologic stressor that is ubiquitous among deployed
military members that can impede glycemic management is
sleep disturbance.4 Sleep quality surveys administered to
military members during and after deployment revealed that
members received signiﬁcantly shorter sleep durations and
sustained more sleep disturbances compared to those who
did not deploy.28 Sleep deprivation and misalignment of circadian rhythms can promote insulin resistance by increasing
counter-regulatory hormones and activating the sympathetic
nervous system.29 The impairment in cognition after disrupted
sleep can also lead to mistakes in medication administration,
leading to excessively high and low glucose excursions.
Related to sleep disturbance is the high prevalence of
mental health problems resulting from deployment such as
depression, post-traumatic stress disorder, and anxiety.30,31
A meta-analysis suggested that depression was signiﬁcantly
associated with worse HbA1c, with an effect size that was
small to moderate.32,33 A proposed mechanism for this psychosomatic interaction involves a more sustained increase in
cortisol experienced by people with depression after a psychologically stressful event compared with those without
depression.34 Likewise, anxiety and post-traumatic stress
disorder have also been associated with poorer glycemic
control.35,36
e607
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members as our data collection method was not designed to
readily capture this information. Even so, we are not aware
of any reports of hypoglycemia causing signiﬁcant problems
for service members with diabetes in the deployed setting.
Although it is well recognized that sulfonylureas can
cause hypoglycemia, the decision to continue them may
have been partly due to the lack of incentive to modify medications for those who are already meeting glycemic targets.
Despite the availability of other oral agents with better safety
proﬁles, HbA1c stability on a sulfonylurea-containing regimen may have been viewed more favorably by military providers since medication adjustments and routine diabetes
clinical encounters are generally not expected in a deployed
setting.13 Additionally, choosing a sulfonylurea as a ﬁrst or
second-line agent was consistent with the prevailing prescribing practice within our study period. An analysis on
prescription trends for diabetes medications ﬁlled in U.S.
retail pharmacies from 2003 to 2014 demonstrated that the
volume of sulfonylurea prescriptions remained constant
despite the emergence of newer agents.18 In this study, those
on sulfonylureas maintained a stable HbA1c, but the possibility of hypoglycemic events during their deployment cannot be excluded.
Surprisingly, nine members were deployed while on insulin,
a medication that is more challenging to manage in a deployed
environment. Severe hypoglycemia, sustained hyperglycemia,
and other catastrophic glycemic crises can occur when critical
tasks acutely arise causing missed meals and ill-timed insulin
doses. Additionally, appropriate storage facilities are either unreliable or simply non-existent in a combat theater. The Food and
Drug Administration (FDA) recommends that insulin be refrigerated at approximately 36°F (2.2°C) to 46°F (7.8°C). It can
maintain its integrity if left at room temperature (59°F [15°C]
−86°F [30°C]) for up to 28 d, but exposure to extreme heat or
freezing temperatures will reduce its potency.19 Unfortunately,
over the course of a deployment, a member may transition several times to different locations and climates, precluding reliable
access to appropriate storage facilities or a pharmacy. In contrast
to those on oral medications, those who deployed on insulin
had higher HbA1c values prior to deployment, which may
reﬂect more advanced disease, but also permissive hyperglycemia to avoid hypoglycemic episodes. Because of the challenges
inherent to deployments, relaxation of glycemic targets among
insulin-users may have been a practical necessity.
The latter portion of our study period saw the emergence
of newer medication classes without hypoglycemic side
effects, but because of timing of DoD formulary approval
and other medication factors, they were not prescribed as
commonly. The safety proﬁle of DPP-4 inhibitors is favorable enough for deployment, but was likely not utilized as
often due to the novelty of the drug class at the time.
However, the DoD now recognizes the safety of this drug
class as some Air Force aviators, a group rigorously monitored for medical complications, are retained in their aviation
duties despite taking DPP-4 inhibitors. 20 GLP-1 RA may

Effect of Military Deployment on Diabetes Mellitus in Air Force Personnel

Strengths and Limitations
This study is the ﬁrst attempt to characterize the impact of
military deployments on Air Force service members with
diabetes. A major strength of this study is that it was able to
capture data from every deployment in the time period studied, such that a comprehensive review could be accomplished, accounting for HbA1c change, weight change, and
medication use. Prior to this analysis, the number of Air
Force members who deployed with diabetes was unknown.
There are also several limitations of this study. As with
any large data set review, none of the service members with
diabetes were interviewed, and none of the speciﬁc medical
records were scrutinized, so speciﬁc details about each member were lacking. We can only speculate on the reasons why
only a third of the members had a HbA1c drawn within ideal
intervals before and after deployment. From our own deployment experiences, various pre- and post-deployment training
and activities can take precedence over medical follow-ups.
Additionally, as previously mentioned, our study design did
not allow us to capture the incidence of hypoglycemic events
in members using insulin or sulfonylureas, which could have
an adverse impact in certain deployed scenarios. Even so,
we are not aware of any reports indicating this issue to be a
signiﬁcant problem. Perhaps, the largest limitation was the
lack of information about the deployment location for each
member, which was not attainable in our methodology. As a
result, we were not able to make associations about the austerity of particular deployment locations with the measures
of interest in this study. Of course, the majority of deployments for military personnel in our study interval occurred
in Afghanistan and Iraq, and virtually all of the locations
had reduced medical services compared to what would be
available at their original duty stations. As our methodology
prevented us from reviewing the speciﬁc environment for
each member in the study, determinations about which environments led to our results cannot be made. It is also possible
that service members with diabetes, although allowed to
deploy, may have been restricted to less austere environments because of their condition. Even so, it is reasonable to
assume that this study provides data that can be used to formulate policy regarding deployment of members to facilities
with standard medical and food services found in ﬁxed locations. This data could also be applicable in civilian settings
in which a person with diabetes desires to participate in
activities in an underserved part of the world.
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This study provides insight into how service members
with diabetes respond to deployment and can serve as a
resource for military medical providers and leaders seeking
guidance on the feasibility of deploying this population.
Some members with diabetes, even those who require medications, appear to be adequately “ﬁt to ﬁght” as their HbA1c
were mostly maintained within reasonable levels. However,
medical practice can be improved by thoughtful consideration of a member’s glycemic management and medication
requirements prior to deployment, as well as encouraging
timely follow-up upon return. In the future, a prospective
design could overcome several of the limitations in this
study and provide a more robust basis to guide clinical decisions and policy development.
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